IM Biologics
IM Biologics is a biotech company in Suwon, South Korea, founded in 2020.
Innovative Medicines based on ImmunoModulatory Biologics
- Headquarters
- Suwon
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- imbiologics.com
About
IMBiologics (IMB) is a South Korean biopharmaceutical company founded in August 2020, dedicated to developing innovative antibody-based therapeutics for immunology, inflammation, and oncology. Leveraging its proprietary IM-OpDECon antibody modality engineering platform, IMB designs differentiated biologics targeting autoimmune diseases and immuno-oncology with unmet medical needs. The company is headquartered in Suwon, Gyeonggi-do, Korea, and is listed on the KOSDAQ exchange, having achieved a landmark $944.8 million global licensing deal for its lead asset IMB-101.
Summary
It lists 11–50 employees.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/im-biologics"><img src="https://indexed.vc/api/badge/company/im-biologics" alt="IM Biologics on Indexed.vc" width="260" height="76" /></a>